scholarly journals Prognostic significance of p53 immunoexpression in the survival of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy

2013 ◽  
Vol 6 (6) ◽  
pp. 1611-1615 ◽  
Author(s):  
LI LI ◽  
MANABU FUKUMOTO ◽  
DUO LIU
Author(s):  
Nattinee Charoen ◽  
Kitti Jantharapattana ◽  
Paramee Thongsuksai

Objective: Programmed cell death ligand 1 (PD-L1) and mammalian target of rapamycin (mTOR) are key players in host immune evasion and oncogenic activation, respectively. Evidence of the prognostic role in oral squamous cell carcinoma (OSCC) is conflicting. This study examined the associations of PD-L1 and mTOR expression with 5-year overall survival in OSCC patients. Material and Methods: The expressions of PD-L1 and mTOR proteins were immunohistochemically evaluated on tissue microarrays of 191 patients with OSCC who were treated by surgery at Songklanagarind Hospital, Thailand from 2008 to 2011. Cox regression analysis was used to determine independent prognostic factors. Results: PD-L1 expression was observed in 14.1% of cases while mTOR expression was present in 74.3% of cases. Females were more likely to have tumors with PD-L1 (p-value=0.007) and mTOR expressions (p-value=0.003) than males. In addition, lower clinical stage and well differentiated tumor are more likely to have mTOR expression (p-value= 0.038 and p-value<0.001, respectively). Cox regression analysis showed that age, tumor stage, nodal stage, combined surgical treatment with radiation or chemoradiation therapy, surgical margin status, PD-L1 expression and mTOR expression are independent prognostic factors. High PD-L1 expression (hazard ratio (HR) 3.14, 95% confidence interval (CI), 1.26–7.79) and high mTOR expression (HR 1.69, 95% CI, 1.00–2.84) are strong predictors of poor outcome. Conclusion: A proportion of OSCC expressed PD-L1 and mTOR proteins. Expression of PD-L1 and mTOR proteins are strong prognostic factors of OSCC.


Head & Neck ◽  
2009 ◽  
Vol 31 (12) ◽  
pp. 1544-1556 ◽  
Author(s):  
Neelam G. Shah ◽  
Trupti I. Trivedi ◽  
Rajen A. Tankshali ◽  
Jignesh V. Goswami ◽  
Dhaval H. Jetly ◽  
...  

2012 ◽  
Vol 10 (1) ◽  
pp. 51-59 ◽  
Author(s):  
Diego Mauricio Bravo-Calderón ◽  
Denise Tostes Oliveira ◽  
Aparecido Nilceu Marana ◽  
Suely Nonogaki ◽  
André Lopes Carvalho ◽  
...  

2019 ◽  
Vol 27 (7) ◽  
pp. 713-721 ◽  
Author(s):  
Ryuta Nakao ◽  
Eiichi Konishi ◽  
Hitoshi Fujiwara ◽  
Eigo Otsuji ◽  
Isao Yokota ◽  
...  

Background. The aim of this study was to assess the prognostic significance of residual cancer volume (RCV) in patients with esophageal squamous cell carcinoma (ESCC) who received esophagectomy after neoadjuvant chemotherapy. Methods. We measured RCV by using complete stepwise sections at 6- to 8-mm intervals obtained from 81 ESCC patients with clinical stages IB to III. RCV was defined as the summation of all products of residual cancer area and thickness, and its cutoff value was set by receiver operator characteristic curve analysis on 3-year disease-specific survival (DSS). The multivariate analyses were performed in comparison with histopathological factors including tumor regression grades according to the Japanese Classification of Esophageal Cancer (TRG-JPN) or reported by Becker et al (TRG-Becker). Results. The range of RCV was 0 to 49.3 cm3 (median = 1.4 cm3), and the cutoff value was set at 1.0 cm3 (sensitivity = 78%; specificity = 68%). In the Kaplan-Meier curve analysis with the log-rank test, RCV > 1.0 cm3 predicted poorer prognosis for relapse-free survival (RFS; 5-year RFS rate, 12% vs 47%; P < .001) and DSS (5-year DSS rate, 27% vs 61%; P < .001). The multivariate analyses by the Cox hazards model revealed that RCV > 1.0 cm3 was a factor predicting poor prognosis for RFS ( P = .013; hazard ratios [HR] = 2.62) and DSS ( P = .028; HR = 2.56) compared with histopathological factors including TRG-JPN; RFS ( P = .014; HR = 3.03) and DSS ( P = .045; HR = 2.71) compared with histopathological factors including TRG-Becker. Conclusions. The study suggested that determining RCV is a new method of predicting prognosis in ESCC patients after neoadjuvant chemotherapy.


2016 ◽  
Vol 7 (7) ◽  
pp. 758-767 ◽  
Author(s):  
Shang Xie ◽  
Ying Liu ◽  
Xue Qiao ◽  
Rui-Xi Hua ◽  
Kan Wang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document